What is NDC 50268-176?

50268-176 is the product NDC for cilostazol, Cilostazol 50 mg/1 tablet, listed with the FDA by AvPAK. It has 1 package NDC, shown above in 10- and 11-digit form.

AvPAK, NDC labeler code 50268. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for cilostazol?

15 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

cilostazol NDC 50268-176 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)50268-176Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50268-0176Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50268-176-15	5026801761550268017615	50 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-176-15) / 1 TABLET in 1 BLISTER PACK (50268-176-11)Marketed from Oct 18, 2016

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): cilostazol
Generic name (nonproprietary): cilostazol
Active ingredients: Cilostazol — 50 mg/1
Dosage form: Tablet
Route: Oral
Labeler: AvPAKNDC labeler code 50268
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077030
Marketing start: Oct 18, 2016
Listing expires: Dec 31, 2027
Other FDA classes: Phosphodiesterase 3 Inhibitors (Mechanism)
Identifiers: Product ID 50268-176_47bc4cad-6c05-e6d6-e063-6294a90a5c2dSPL ID 47bc4cad-6c05-e6d6-e063-6294a90a5c2dSPL set ID aec462c8-e225-f520-cae5-80049151c0ffRxCUI 242461, 242462UNII N7Z035406B
Pharmacologic class: Phosphodiesterase 3 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450268017615 followed by a unit qualifier and the quantity

Package 50268-0176-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 6, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. Cilostazol is a phosphodiesterase III inhibitor (PDE III inhibitor) indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 50268-176

What is NDC 50268-176?: 50268-176 is the product NDC for cilostazol, Cilostazol 50 mg/1 tablet, listed with the FDA by AvPAK. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: cilostazol.
What is the active ingredient?: Cilostazol.
Who is the labeler?: AvPAK, NDC labeler code 50268. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for cilostazol?: 15 other product NDCs are listed under this name. See all cilostazol NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other cilostazol NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
cilostazol	Cilostazol 100 mg/1	TabletOral	AvKARE	42291-453	42291-0453-60
cilostazol	Cilostazol 100 mg/1	TabletOral	Aphena Pharma Solutions - Tennessee, LLC	71610-813	71610-0813-26
Cilostazol	Cilostazol 50 mg/1	TabletOral	direct rx	72189-116	72189-0116-60
Cilostazol	Cilostazol 50 mg/1	TabletOral	Slate Run Pharmaceuticals, LLC	70436-156	70436-0156-06
Cilostazol	Cilostazol 100 mg/1	TabletOral	Slate Run Pharmaceuticals, LLC	70436-157	70436-0157-06
cilostazol	Cilostazol 100 mg/1	TabletOral	AvPAK	50268-177	50268-0177-15
Cilostazol	Cilostazol 100 mg/1	TabletOral	Teva Pharmaceuticals USA, Inc.	0093-2064	00093-2064-0600093-2064-50
Cilostazol	Cilostazol 100 mg/1	TabletOral	Bryant Ranch Prepack	63629-8795	63629-8795-01
Cilostazol	Cilostazol 50 mg/1	TabletOral	Teva Pharmaceuticals USA, Inc.	0093-2065	00093-2065-06
Cilostazol	Cilostazol 50 mg/1	TabletOral	Bryant Ranch Prepack	63629-8796	63629-8796-01

All 16 cilostazol NDCs

Other NDCs under ANDA 077030

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 077030
Product	Strength	Form · route	Labeler	Product NDC
cilostazol	Cilostazol 100 mg/1	TabletOral	AvKARE	42291-453
cilostazol	Cilostazol 100 mg/1	TabletOral	AvPAK	50268-177
cilostazol	Cilostazol 50 mg/1	TabletOral	Apotex Corp.	60505-2521
cilostazol	Cilostazol 100 mg/1	TabletOral	Apotex Corp.	60505-2522
cilostazol	Cilostazol 100 mg/1	TabletOral	Aphena Pharma Solutions - Tennessee, LLC	71610-813
cilostazol	Cilostazol 100 mg/1	TabletOral	Aphena Pharma Solutions - Tennessee, LLC	71610-822